Personalized vaccine shows promise in fighting pancreatic cancer recurrence
NCT ID NCT04627246
First seen May 12, 2026 · Last updated May 12, 2026
Summary
This early-phase study tests a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy and an immunotherapy drug (nivolumab), for people with pancreatic cancer that was surgically removed. The goal is to see if this combination is safe and can help prevent the cancer from coming back. The study involves 14 participants and focuses on feasibility and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUV Oncology Department
Lausanne, Canton of Vaud, 1011, Switzerland
Conditions
Explore the condition pages connected to this study.